Kures

About:

Kures is a pre-clinical-stage biopharmaceutical startup that develops opioid-based treatments for depressive disorder.

Description:

Kures is a pre-clinical-stage biopharmaceutical startup that develops opioid-based treatments for depressive disorder. The biopharmaceutical company is also interested in addressing other challenging indications in the psychiatry and physical pain arena using its portfolio of novel small molecules. It is currently operating in Stealth mode. Andrew Kruegel established the biotech company in 2017 in Dobbs Ferry, New York.

Total Funding Amount:

$4.24M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Dobbs Ferry, New York, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)kuresinc.com

Founders:

Andrew Kruegel

Number of Employees:

1-10

Last Funding Date:

2019-08-28

IPO Status:

Private

Industries: